Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026
ADPT vs ATYR: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
ATYR Captures Overall Composite Edge (34.3 SELL vs 43.2 HOLD), While ADPT Leads 4–2 on Growth & Valuation Pillars
ATYR Overall Winner
6-Pillar Tally: ADPT 4 – 2 ATYR
Matrix Metrics: ADPT 5 – 3 ATYR
As of Nov 17, 2026, aTyr Pharma, Inc. (ATYR) captures the overall head-to-head institutional edge over Adaptive Biotechnologies Corporation (ADPT) on higher Unified Composite conviction (34.3/100 SELL vs. 43.2/100 HOLD) after splitting the core matrix 3–5 (led by Growth & Scale, Profitability & Quality), while ADPT wins 4–2 across the 6-pillar growth and valuation breakdown. ADPT trades at $28.46 (N/M Forward P/E, -16.2% operating margin) versus ATYR at $4.83 (N/M Forward P/E, 0.0% operating margin).
- Composite vs. Pillar Nuance: While ADPT currently prints a higher short-term Unified Composite Score (43.2/100 HOLD vs. ATYR 34.3/100 SELL), ATYR captures the overall institutional head-to-head verdict (3–5 matrix metrics and 2–4 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -16.2% operating margin) and revenue trajectory (+0.0% vs. -10.7% YoY).
Executive Snapshot Side-by-Side Composite Ratings & Technical Regime
Ask Alpha AI About ADPT vs ATYR
ADPT
Adaptive Biotechnologies Corporation Common Stock
$28.46
+2.12% 1D
Market Cap
$4.7B
TTM Revenue
$298M
Forward P/E
N/M
Beta / 30D Vol
1.71β · 59% Vol
Unified Composite Score
43.2
HOLD
Tech 15.0
Fund 42.0
Flow 68.0
Mom 50.0
Weinstein Technical Phase
Markup · Hold / add on dips
ATYR
Head-to-Head Winner
aTyr Pharma, Inc. Common Stock
$4.83
-7.82% 1D
Market Cap
$15.6M
TTM Revenue
N/A
Forward P/E
N/M
Beta / 30D Vol
-9.57β · 13806% Vol
Unified Composite Score
34.3
SELL
Tech 50.0
Fund 36.0
Flow 69.0
Mom 50.0
Weinstein Technical Phase
Markup · Hold / add on dips
6-Pillar Scorecard Institutional Category Breakdown (ADPT 4 – 2 ATYR)
1. Valuation Multiples
ADPT
Forward P/E
N/M
N/M
Trailing P/E
N/M
N/M
PEG Ratio
N/M
N/M
EV / Revenue
16.9x
N/M
2. Growth & Scale
ATYR
Revenue Growth (YoY)
-10.7%
+0.0%
Earnings Growth (YoY)
-70.1%
+0.0%
TTM Revenue (USD)
$298M
N/A
Market Cap
$4.7B
$15.6M
3. Profitability & Quality
ATYR
Gross Margin
46.2%
N/A
Operating Margin
-16.2%
0.0%
Net Profit Margin
-23.7%
0.0%
Return on Equity (ROE)
-36.4%
-93.7%
4. Balance Sheet & Cash Flow
ADPT
Cash Generation (TTM)
-$8.8M
N/A
Cash Flow Margin
-3.0%
N/A
Net Cash / Leverage
$333M Net Debt (2.32x D/E)
$4.9M Net Cash
Dividend Yield
None (0.00%)
None (0.00%)
5. Options & Positioning
ADPT
Options Structure Phase
BREAKOUT
UNCLASSIFIED
Current IV / %ile
78.0% (36th %ile)
154.5% (36th %ile)
Put/Call OI Skew
0.01x (Call-Skewed)
N/A
OBV Trend / Tech Phase
ACCUMULATION · Markup
NEUTRAL · Markup
6. R&D & Supply-Chain Moat
ADPT
OpEx & R&D Intensity
62.4% of Rev ($186M)
N/A
90D R&D Disclosures
0 papers
0 papers
Competitive Moat
Cyclical / Execution-Driven Positioning
Cyclical / Execution-Driven Positioning
Supply-Chain Role
Diagnostics & Research Operator
Biotechnology Operator
Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table
Core Matrix Wins: ADPT (5) vs ATYR (3)| Institutional Metric | ADPT | ATYR | Criterion | Row Edge |
|---|---|---|---|---|
| Market Capitalization | $4.7B | $15.6M | ADPT | |
| Trailing P/E Ratio | N/M | N/M | Tie | |
| Forward P/E Ratio | N/M | N/M | Tie | |
| Revenue Growth (YoY) | -10.7% | +0.0% | ATYR | |
| Operating Margin (TTM) | -16.2% | 0.0% | ATYR | |
| Net Profit Margin | -23.7% | 0.0% | ATYR | |
| Return on Equity (ROE) | -36.4% | -93.7% | ADPT | |
| 52-Week Range Position | 81% ($12–$32) | 60% ($0–$8) | ADPT | |
| Beta / 30D Volatility | 1.71β · 59% Vol | -9.57β · 13806% Vol | ADPT | |
| Unified Institutional Score | 43.2 / 100 (HOLD) | 34.3 / 100 (SELL) | ADPT | |
| Trailing 12M Revenue (USD) | $298M | N/A | Scale | |
| Gross Profit Margin (TTM) | 46.2% | N/A | Quality | |
| PEG Ratio & EV / Revenue | N/M PEG · 16.9x EV/Rev | N/M PEG · N/M EV/Rev | Valuation | |
| Cash Flow & Balance Sheet | -$8.8M ($333M Net Debt (2.32x D/E)) | N/A ($4.9M Net Cash) | Solvency |
Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)
1M Horizon
ATYR +2694.22 pp
3M Horizon
ATYR +794.88 pp
6M Horizon
ATYR +780.4 pp
1Y Horizon
ATYR +439.59 pp
Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | ADPT Revenue | ATYR Revenue | ADPT Op. Margin | ATYR Op. Margin | Margin Leader |
|---|---|---|---|---|---|
| FY2018 | $60M | N/A | -89.4% | N/A | ADPT |
| FY2019 | $90M | $0M | -92.1% | -5445.0% | ADPT |
| FY2020 | $100M | $10M | -155.3% | -152.2% | ATYR |
| FY2021 | $150M | N/A | -135.4% | N/A | ADPT |
| FY2022 | $190M | $10M | -108.0% | -446.8% | ADPT |
| FY2023 | $170M | $0M | -133.3% | -15557.8% | ADPT |
| FY2024 | $180M | $0M | -90.8% | -28899.6% | ADPT |
| FY2025 | $280M | $0M | -20.6% | -40856.3% | ADPT |
Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor
Live Options Phase Tracker
ADPT
BREAKOUT
Current IV
78.0%
IV Percentile
36th %ile
Put/Call OI Skew
0.01x (Call-Skewed)
IV Regime
Balanced (25th–60th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BULLISH
OBV Flow
ACCUMULATION
Exact ADPT Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
ATYR
UNCLASSIFIED
Current IV
154.5%
IV Percentile
36th %ile
Put/Call OI Skew
N/A
IV Regime
Balanced (25th–60th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BULLISH
OBV Flow
NEUTRAL
Exact ATYR Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity
Corporate R&D & Foundry Leaderboard
ADPT Moat Profile
Cyclical / Execution-Driven Positioning
Diagnostics & Research Operator
OpEx & R&D Reinvestment
62.4% of Rev ($186M)
90D Engineering Disclosures
0 Published
ATYR Moat Profile
Cyclical / Execution-Driven Positioning
Biotechnology Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
Investor FAQ ADPT vs ATYR Key Questions & Quantitative Answers
As of Nov 17, 2026, aTyr Pharma, Inc. (ATYR) captures the overall head-to-head institutional edge over Adaptive Biotechnologies Corporation (ADPT) on higher Unified Composite conviction (34.3/100 SELL vs. 43.2/100 HOLD) after splitting the core matrix 3–5 (led by Growth & Scale, Profitability & Quality), while ADPT wins 4–2 across the 6-pillar growth and valuation breakdown. ADPT trades at $28.46 (N/M Forward P/E, -16.2% operating margin) versus ATYR at $4.83 (N/M Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While ADPT currently prints a higher short-term Unified Composite Score (43.2/100 HOLD vs. ATYR 34.3/100 SELL), ATYR captures the overall institutional head-to-head verdict (3–5 matrix metrics and 2–4 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -16.2% operating margin) and revenue trajectory (+0.0% vs. -10.7% YoY).
ATYR leads the Growth & Scale pillar: ADPT posts -10.7% YoY revenue growth and -70.1% YoY earnings growth on $298M TTM revenue (46.2% gross margin, -16.2% operating margin), compared with ATYR at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), ADPT cumulative revenue shifted +366.7% while ATYR shifted +0.0%. In operating R&D and SG&A reinvestment, ADPT deploys 62.4% of Rev ($186M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for ATYR.
ADPT screens cheaper on headline valuation multiples. ADPT trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 16.9x EV/Revenue (-3.0% FCF margin), whereas ATYR trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ADPT (-36.4% ROE) versus ATYR (-93.7% ROE) capital efficiency.
In options market volatility and institutional positioning, ADPT carries 78.0% implied volatility (36th %ile, Balanced (25th–60th %ile)), a 0.01x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a BREAKOUT options structure phase (1.71β · 59% Vol realized risk). By comparison, ATYR carries 154.5% implied volatility (36th %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-9.57β · 13806% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Launch Custom Ticker Comparison →
ATYR vs ADPT · Reverse Pair
ADPT vs BEAM
· Sector Peer
ADPT vs TXG
· Sector Peer
ADPT vs TWST
· Sector Peer
ATYR vs LRMR
· Sector Peer
ATYR vs RZLT
· Sector Peer
INTC vs AMD
· x86 & Data Center CPU
NVDA vs AMD
· AI Accelerators
TSM vs ASML
· Foundry & Lithography
MSFT vs GOOGL
· Hyperscale Cloud & AI
AAPL vs META
· Consumer Ecosystem